MX2018014129A - Pharmaceutical composition comprising eteplirsen. - Google Patents

Pharmaceutical composition comprising eteplirsen.

Info

Publication number
MX2018014129A
MX2018014129A MX2018014129A MX2018014129A MX2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A
Authority
MX
Mexico
Prior art keywords
eteplirsen
pharmaceutical composition
subject
administering
treating
Prior art date
Application number
MX2018014129A
Other languages
Spanish (es)
Inventor
Holt Thomas
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MX2018014129A publication Critical patent/MX2018014129A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Abstract

Provided herein are pharmaceutical compositions comprising Eteplirsen. Also provided herein are methods of treating a muscle disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of the disclosure.
MX2018014129A 2016-05-24 2017-05-24 Pharmaceutical composition comprising eteplirsen. MX2018014129A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340947P 2016-05-24 2016-05-24
US201662429160P 2016-12-02 2016-12-02
PCT/US2017/034265 WO2017213854A1 (en) 2016-05-24 2017-05-24 Pharmaceutical composition comprising eteplirsen

Publications (1)

Publication Number Publication Date
MX2018014129A true MX2018014129A (en) 2019-04-29

Family

ID=59093599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014129A MX2018014129A (en) 2016-05-24 2017-05-24 Pharmaceutical composition comprising eteplirsen.

Country Status (15)

Country Link
US (1) US20190275072A1 (en)
EP (1) EP3463390A1 (en)
JP (1) JP2019516730A (en)
KR (1) KR20190009343A (en)
CN (1) CN109562123A (en)
AU (1) AU2017278699A1 (en)
BR (1) BR112018074299A2 (en)
CA (1) CA3024178A1 (en)
CO (1) CO2018013828A2 (en)
IL (1) IL263040A (en)
MA (1) MA45158A (en)
MX (1) MX2018014129A (en)
SG (1) SG11201809494VA (en)
TW (1) TW201805002A (en)
WO (1) WO2017213854A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (en) 2010-09-01 2016-07-11 日本新藥股份有限公司 Antisense nucleic acid
US20220251551A1 (en) * 2018-06-13 2022-08-11 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
EP4219717A3 (en) * 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
JP2021526807A (en) * 2018-06-14 2021-10-11 サレプタ セラピューティクス， インコーポレイテッド Exon skipping oligomers and oligomeric conjugates for muscular dystrophy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
AU5661386A (en) 1985-03-15 1986-10-13 Stirchak, E. Stereoregular polynucleotide-binding polymers
WO1990002749A1 (en) 1988-09-01 1990-03-22 Forskningscenter Risø Peptide synthesis method and solid support for use in the method
ES2361325T3 (en) 2004-06-28 2011-06-16 The University Of Western Australia OLIGONUCLEÓTIDOS ANTISENTIDO TO INDUCE THE OMISSION OF EXON AND METHODS OF USE OF THE SAME.
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
BR122019021332A8 (en) 2007-11-15 2022-12-06 Avi Biopharma Inc MORPHOLIN OLIGOMER SYNTHESIS PROCESS
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
PT2623507T (en) 2010-09-30 2016-12-23 Nippon Shinyaku Co Ltd Morpholino nucleic acid derivative
WO2013082551A1 (en) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
CN103933549A (en) * 2013-01-17 2014-07-23 刘海俊 Novel blood vessel chalone eye drop and preparation method thereof
US20140329762A1 (en) * 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy

Also Published As

Publication number Publication date
KR20190009343A (en) 2019-01-28
US20190275072A1 (en) 2019-09-12
CO2018013828A2 (en) 2018-12-28
SG11201809494VA (en) 2018-12-28
EP3463390A1 (en) 2019-04-10
BR112018074299A2 (en) 2019-03-12
CA3024178A1 (en) 2017-12-14
CN109562123A (en) 2019-04-02
AU2017278699A1 (en) 2018-11-15
JP2019516730A (en) 2019-06-20
TW201805002A (en) 2018-02-16
IL263040A (en) 2018-12-31
WO2017213854A1 (en) 2017-12-14
MA45158A (en) 2019-04-10

Similar Documents

Publication Publication Date Title
MX2021009673A (en) Modulators of ror-gamma.
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2017005834A (en) Aadc polynucleotides for the treatment of parkinson's disease.
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
TW201613901A (en) New compounds
MD4733C1 (en) Anti-TIGIT antibodies
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
MX2017004838A (en) Interleukin-15 compositions and uses thereof.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX2017002816A (en) Pyrazolopyridine derivatives and their use in therapy.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2017006464A (en) Tlr inhibitor and bruton's tyrosine kinase inhibitor combinations.
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
MX2017006437A (en) Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain.
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
EA201792571A1 (en) THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2019001634A (en) Amide compounds, pharmaceutical compositions thereof, and methods of using the same.
MX2017012022A (en) Organic compounds.
MX2020000636A (en) Synthetic proteins and therapeutic uses thereof.
MX2017009608A (en) Anti-cancer compounds.